News
Merck chief quits as further material on Vioxx emerges
BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7500.1101-a (Published 12 May 2005) Cite this as: BMJ 2005;330:1101- Ray Moynihan
- Sydney
The chief executive officer and chairman of Merck, Raymond Gilmartin, resigned unexpectedly last week, the same day a damning US Congress report on the company was released.
Even though Mr Gilmartin stepped down hurriedly a year ahead of schedule, Merck's official position is that the resignation was not connected to the growing global controversy over its anti-arthritis drug rofecoxib (Vioxx), which was withdrawn from the market late last year, after studies produced evidence …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.